Contacts

Martin Wermke, Prof. Dr.

CONTACT

+49 351 458 16226 impalux-studie@ukdd.de

Sponsors

Lead Sponsor

Technische Universität Dresden

Collaborators

Deutsche Krebshilfe e.V., Bonn (Germany)
Universitätsklinikum Köln

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•For all:
•Written informed consent of the patient
•Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM)
•Advanced lung cancer with non-curative treatment option (NSCLC)
•No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1
•PD-L1 expression on tumor cells (TPS \< 50%)
•Cohort A:
•Previously untreated NSCLC without curative treatment options
•Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy
•Scheduled to undergo immune(chemo)therapy
•Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy
•Cohort B:
•Any line of progression after firstline immune(chemo)therapy
•Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment

Exclusion Criteria

•Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator
•Incapability of understanding the purpose and possible consequences of the trial
•Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results

Related studies

RECRUITING

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

NCT07356544 · NSCLC (Advanced Non-small Cell Lung Cancer), HER2

RECRUITINGPhase 3

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

NCT06956001 · EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)

RECRUITINGPhase 1/2

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NCT06706076 · NSCLC (Advanced Non-small Cell Lung Cancer)

RECRUITINGPhase 1/2

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

NCT07371663 · Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), and more

RECRUITING

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT07288632 · Venous Thromboembolism (VTE), NSCLC (Advanced Non-small Cell Lung Cancer)

View all related studies →

Immune-Marker Platform for Patients With Advanced Lung Cancer

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Contacts

Sponsors

Related studies

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer

Trial snapshot

Condition

Locations shown

For caregivers